TY - JOUR T1 - Atrial fibrillation and kidney function: A bidirectional Mendelian randomization study JF - medRxiv DO - 10.1101/2020.07.31.20166207 SP - 2020.07.31.20166207 AU - Sehoon Park AU - Soojin Lee AU - Yaerim Kim AU - Yeonhee Lee AU - Min Woo Kang AU - Kwangsoo Kim AU - Yong Chul Kim AU - Seung Seok Han AU - Hajeong Lee AU - Jung Pyo Lee AU - Kwon Wook Joo AU - Chun Soo Lim AU - Yon Su Kim AU - Dong Ki Kim Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/04/2020.07.31.20166207.abstract N2 - Aims To investigate the causal effects between atrial fibrillation (AF) and kidney function.Methods and Results We performed a bidirectional Mendelian randomization (MR) analysis implementing the results from large-scale genome-wide association study (GWAS) for estimated glomerular filtration rate (eGFR) by the CKDGen (N = 1,046,070) and for AF (N = 588,190) to determine genetic instruments. A bidirectional two-sample MR based on summary-level data was performed. Inverse variance weighted method was the main MR method. For replication, an allele-score based MR was performed by individual-level data within the UK Biobank cohort of white British ancestry with eGFR values (N= 321,260).The genetical predisposition to AF was significantly associated with lower eGFR [beta - 0.002 (standard error 0.0005), P < 0.001] and higher risk of chronic kidney disease [beta 0.051 (0.012), P < 0.001], and the significance remained in various MR sensitivity analyses. The causal estimates were consistent when we limited the analysis to individuals of European ancestry. The genetically predicted eGFR did not show significant association with risk of AF [beta −0.189 (0.184), P = 0.305]. The results were similar in allele-score based MR, as allele-score for AF was significantly associated with lower eGFR [beta −0.069 (0.021), P < 0.001] but allele-score for eGFR did not show significant association with risk of AF [beta −0.001 (0.009), P = 0.907].Conclusions Our study supports that genetical predisposition to AF is a causal risk factor for kidney function impairment. However, effect from kidney function on AF was not identified in this study.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Industrial Strategic Technology Development Program - Development of bio-core technology (10077474, Development of early diagnosis technology for acute/chronic renal failure) funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea) and a grant from SNU R&DB Foundation (800-20190571). The study was performed independently by the authors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was performed in accordance with the Declaration of Helsinki. The study was approved by the institutional review boards of Seoul National University Hospital (No. E-1910-044-1067) and the UK Biobank consortium (application No. 53799). The genetic instrument implemented in this study has been previously published, and summary-level data were utilized. The summary statistics for the CKDGen genome-wide association study (GWAS) meta-analysis for kidney function traits are in the public domain (URL: https://ckdgen.imbi.uni-freiburg.de/). The summary statistics for AF trait are available on the Cardiovascular Disease Knowledge Portal (URL: https://www.braodcvdi.org/). As the study investigated anonymous database or summary-level data, requirement for informed consent was waived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this article were accessed from the CKDGen consortium (URL: https://ckdgen.imbi.uni-freiburg.de/) the Cardiovascular Disease Knowledge Portal (URL: https://www.braodcvdi.org/). The UK Biobank data for this study will be made available in the UK Biobank consortium (biobank.ctsu.ox.ac.uk). ER -